- Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals
- Improving access to reliable diagnostics for disease management in countries with the highest burden
- Early detection of infectious diseases with diagnostics helps clinicians save lives
Basel, 22 July 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. The expansion of the Global Access Program highlights Roche’s commitment to improve access to cost-effective resources, implement scale-up programs, and contribute to the elimination of diseases in the regions with the greatest need.
With effective treatment options for these infectious agents and improved patients access to diagnostics, early detection can help save lives and ease suffering,
said Michael Heuer, CEO Roche Diagnostics.
As the leader in infectious disease diagnosis testing, Roche is dedicated to support goals on eradicating diseases globally.
Access to cutting-edge, best in class diagnostic test results means more patients being appropriately diagnosed and well treated, resulting in lives saved,
stated David Ripin, Chief Science Officer of the Clinton Health Access Initiative (CHAI).
We welcome Roche’s decision to expand access to tests for hepatitis, tuberculosis, and HPV (the leading cause of cervical cancer) to their Global Access Program, providing health systems with transparent and consistent pricing to these important tests in addition to the HIV viral load and early infant diagnostics already established in the program. CHAI values Roche’s continued partnership in the effort to make diagnostics seamlessly available in well optimized diagnostic lab systems throughout the world.
Accessible pricing can be the difference between a patient getting a quality diagnosis or not,
said Catharina Boehme, CEO of the Foundation for Innovative New Diagnostics (FIND) – a global non-profit devoted to the development and delivery of diagnostics for diseases that include TB and HCV.
FIND is proud to have worked with Roche to expand the Global Access Program for these deadly diseases, leveraging our support for its TB assay.
Access to screening, early detection and prevention of transmission reduces the spread of disease. Tuberculosis is a major health crisis and is the leading cause of infectious disease deaths worldwide. Access to hepatitis diagnostic tests for HBV and HCV will improve the outlook of eliminating these chronic infections. And screening with HPV DNA testing can more accurately identify women at risk for cervical cancer than other screening methods . With vaccination and proper screening, cervical cancer is a preventable disease . Importantly, infection with HPV has been found to increase the risk of HIV transmission for both men and women4. Similarly, women living with HIV are four to 10 times more likely to develop cervical cancer. Screening for co-infection (HIV+ HPV) can significantly improve disease management decisions and enable appropriate patient care.
In total, the Global Access Program now includes molecular diagnostics for HIV-1 viral load, HIV-1 and HIV-2 early infant diagnosis, the cobas® Plasma Separation Card - an innovative plasma collection device, MTB and MTB - RIF/INH, Hepatitis B and C, and Human Papillomavirus. All these assays run on the cobas® 4800/6800/8800 platforms for various testing volume needs enabled by the cobas® Plasma Separation Card that transports samples from remote areas/sites to the central lab for further processing.